Skip to main content

Table 1 Effects of antiretroviral combination therapy with nelfinavir, saquinavir, and two nucleoside analogues upon CSF and plasma HIV-1 RNA, CSF and serum neopterin, CSF and serum β2-microglobulin (β2 m), CSF monocytic cell count, CD4+ T- cell count, albumin ratio, and IgG index.

From: Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study

  Baseline Week 12 Week 48
CSF HIV-1 RNA (log10 copies/mL)    
Median (range) 4.19 (2.20–5.40) 1.54 (1.28–2.27) 1.59 (1.28–3.10)
No. of patients < 1.70 log10 copies/mL 0/8 6/8 5/7
Plasma HIV-1 RNA (log10 copies/mL)    
Median (range) 5.04 (3.85–5.58) 1.60 (1.28–2.50) 1.63 (1.28–5.29)
No. of patients < 1.70 log10 copies/mL 0/8 4/8 5/7
CSF neopterin (nmol/L)    
Median (range) 25.5 (11.1–74.0) 10.7 (6.5–25.6) 7.0 (3.8–18.2)
No. of patients = 4.3 nmol/L 0/8 0/8 1/7
Serum neopterin (nmol/L)    
Median (range) 16.4 (9.0–44.9) 10.1 (6.0–22.3) 7.0 (4.4–70.1)
No. of patients = 8.8 nmol/L 0/8 4/8 4/7
CSF β2 M (mg/L)    
Median (range) 2.65 (1.10–7.10) 1.40 (0.70–3.10) 0.90 (0.50–1.60)
No. of patients = 2.2 mg/L 3/8 7/8 8/8
Serum β2 M (mg/L)    
Median (range) 3.40 (1.70–4.50) 2.40 (1.40–3.30) 1.50 (1.30–4.30)
No. of patients = 2.4 mg/L 3/8 4/8 5/7
CSF monocytic cell count (x106/L)    
Median (range) 11 (1–20) 1 (0–7) 1 (0–3)
No. of patients = 4 × 106 cells/L 3/7 7/8 7/7
CD4+ T-cell count (cells × 106/L)    
Median (range) 200 (20–310) 305 (100–390) 330 (110–450)
No. of patients = 200 cells × 106/L 4/8 6/8 7/7
Albumin ratio    
Median (range) 3.5 (2.1–10.8) 3.2 (2.1–11.8) 3.6 (1.8–3.8)
No. of patients with normal values 7/8 7/8 7/7
IgG index    
Median (range) 0.98 (0.49–1.47) 0.88 (0.57–2.24) 0.70 (0.48–1.54)
No. of patients < 0.63 1/8 1/8 2/7